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ABSTRACT 
Background: Liver surgery has undergone significant developments over the last three 
decades. However, population-based data are scarce, and there is limited knowledge of the 
impact on mortality and possible treatment modalities of a feared complication following 
hepatectomy, post-hepatectomy liver failure (PHLF). In theory, extracorporeal liver support 
with the Molecular Adsorbent Recirculating System (MARS) might have several positive 
effects in patients with PHLF. Until today, only very few single-center experiences have been 
reported with overall poor patient outcome. However, controlled, prospective data for the use 
of MARS in patients with PHLF are missing. 
Aims: To investigate long-term results after hepatectomy in Sweden in a population-based 
setting. To evaluate the impact of PHLF on short-term mortality. To retrospectively analyze 
the outcome of patients with PHLF being treated with MARS. To prospectively evaluate 
safety and feasibility of an intensified MARS treatment protocol in patients with PHLF. 
Methods: In paper I and II, data between 2002 and 2011 from different patient registries 
were used to assess outcome related to different types of liver resections and differential 
diagnosis. In paper II, a part of the data from paper I (between 2005 – 2009) were used to 
identify patients who died within 90 days from surgery. Data were then completed with 
additional information from local patient journals at the respective hospital. For paper III, all 
patients who were treated with MARS for PHLF at Karolinska University Hospital Huddinge 
and Hospital Clinic, Barcelona, were retrospectively analyzed. For paper IV, a prospective 
pilot study was performed, including all patients with PHLF between 1st of December 2012 
and 30th of May 2015. Safety, feasibility, and outcome were assessed. 
Results: Liver resections are performed with a very low short-term mortality and favorable 
long-term outcomes. 5-year survival in patients resected for colorectal liver metastasis 
(CRLM) was around 60%, and re-resection for CRLM significantly improved long-term 
survival. In a population-based setting, PHLF is whether the leading cause or significantly 
contributes to 90-day mortality, in more than 40% of all cases. Our data confirmed known 
risk factors for PHLF like extended hepatectomy or hepatectomy due to cholangiocarcinoma. 
In a retrospective series, 13 patients were identified who have been treated with MARS due 
to PHLF. A trend towards improved long-term survival was seen in patients being treated 
early and more frequent after hepatectomy. In a prospectively, controlled cohort study we 
found it to be safe and feasible to initiate MARS treatment in patients with PHLF early after 
hepatectomy according to a standardized treatment protocol. Short and long-term survival 
was improved compared to a historical control group. 
Conclusion: In Sweden, liver resections are performed with favorable outcome both in 
regards to short-term and long-term results. PHLF is even in a population-based setting the 
single most important factor causing short-term mortality after hepatectomy. It is safe and 
feasible to use MARS in patients with PHLF early after hepatectomy and both short- and 
long-term survival might be improved. 
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1 INTRODUCTION 
Liver resection has gone trough a tremendeous development over the last decades and 
represents standard-of-care for treatment of the majority of liver tumors (1-4). Because of this 
progress in liver surgery, the limits of resectability for many primary and secondary liver 
tumors have extended along with improved outcome (5). Though, short-term mortality after 
hepatic resection has steadily decreased and today its incidence ranges from 2% to 5%. 
However, those figures are mostly generated from single, high volume centres (2, 6) or 
publications that use specific, non-population-based data as source (7, 8). Only few studies 
strive after a population-based approach. However, those publications elucidate only very 
short study periods (9, 10) or cannot provide results on long-term survival (11, 12).  
Posthepatectomy liver failure (PHLF) has been identified as a major risk factor for mortality 
after liver resection. According to different studies, the incidence of PHLF varies largely 
between 0-30% and may be accounted as the main reason of postoperative mortality related 
to liver surgery (reported figures ranging from 18% to 75%) (13-18). Furthermore, PHLF 
causes prolonged stay in intensive care units, prolonged hospitalisation and up to 4 times 
higher overall treatment costs (19). So far, known major risk factors for postoperative liver 
failure are comorbidity, a pre-existent liver disease and a small remnant liver volume after 
surgery (14, 20). Despite its potentially fatal impact the complex pathophysiology of PHLF is 
still poorly understood and treatment options are very limited. Currently, there are no specific 
treatment options for PHLF and management is mainly restricted to resolve complications 
like bile leakage, infections as well as the prevention of further liver damage caused by e.g., 
thrombosis or hemorrhage as well as administration of liver toxic drugs (14, 21). More 
specific treatment options might be found in extracorporeal liver support therapies. Different 
devices and techniques have been developed during the last decades, mainly to treat acute 
liver failure or bridge patients to liver transplantation (22). Enormous efforts have been 
undertaken in the development of bio-artificial devices that could not only contribute to  
detoxification but also cover other tasks of liver function like synthesis of coagulation factors 
(23). However, due to limited availability those devices are not clinically implemented yet. In 
contrast, today there are other, Albumin-based devices available, mainly focusing on 
detoxification, such as the Single Pass Albumin Dialysis (SPAD) or the Molecular Adsorbent 
Recirculating System (MARS) (24). The MARS device has due to different reasons become 
the most popular amongst all liver support devices (25). However, until today there is no 
prospective, controlled study evaluating possible beneficial effects of this treatment in 
patients with PHLF. 
In summary, a population-based analysis of mortality and long-term survival after liver 
resections as well as the elucidation of factors contributing to mortality and in particular to 
post-hepatectomy liver failure would be highly beneficial. Furthermore it is crucial to further 
determine whether or not MARS has a potential value in the treatment of patients with PHLF. 
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2 BACKGROUND 
 
2.1 HEPATECTOMY - HISTORICAL BACKGROUND AND DEVELOPMENT OF 
LIVER SURGERY 
In modern literature, the first scientific reports describing hepatectomy as a possible treatment 
for liver diseases were published in 1888 by the German surgeon Carl Johann August 
Langenbuch who resected the left liver lobe of a patient, ligating the vessels and bile ducts 
(26). The first procedures describing liver resection for gallbladder cancer were published in 
1901 by Stevens (27) and in 1905 by Hutchinson (28), both performing a wedge resection of 
the liver in order to remove a gallbladder cancer they concurrently found with gallstone 
disease. Since then, liver surgery experienced a tremendous development.  
The probably most essential improvements liver surgery went through, took place from the 
1950´s onwards. Firstly, Claude Couinaud described the anatomy of the liver in a new way, 
dividing it into 8 functional segments with individual blood supply and outflow along with 
segmental bile drainage. This still serves as the gold standard for today’s liver surgery (29). 
However, it took almost 30 years until the French surgeon Henri Bismuth described liver 
resections based on these novel anatomic findings, thus founding modern anatomical liver 
surgery (30). Further technical advancement, like the introduction of ultrasound (31, 32), 
novel surgical techniques like clamping of the portal triad (33) along with improved technical 
equipment for liver transection (34-36) contributed to the rapid development of liver surgery 
over the last decades. 
A key issue of modern liver surgery is the potential of the liver to recover after partial 
hepatectomy; a fact known since the ancient Greek mythology and the myth of Prometheus 
(37). Today, liver regeneration after hepatectomy probably is the best-described human 
model of organ recovery (38-41), and hepatectomies with resection of up to 80% of the liver 
volume are performed safely in expert centers around the world (42-44). In recent years, the 
borders of resectability have been pushed even further by introducing techniques to increase 
the future remnant liver (FLR), like portal vein occlusion techniques (45, 46) or two-step 
hepatectomies (47, 48). The latest development within liver surgery is the so-called in-situ 
split or ALPPS (Associating Liver Partition and Portal vein Ligation for Staged 
hepatectomy), a specific 2-step procedure for patients with a too small future liver remnant. 
Initially described by Schnitzbauer et al. in 2012 (49), this technique has the potential to push 
the borders of resectability even further (50, 51). 
2.2 OUTCOME AFTER HEPATECTOMY FOR MALIGNANT DISEASES 
Malignant tumors in the liver originate from the liver itself (intra- and extrahepatic bile duct 
cancer, gallbladder cancer, hepatocellular cancer) or from metastasis of extra-hepatic cancers. 
Hepatectomy for primary liver cancers, especially peri-hilar cholangiocarcinoma, remain 
challenging and most patients are un-resectable at time of diagnosis or need pre-treatment to 
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release biliary obstruction or increase the FLR (52). After resection of the tumor, those 
patients have a poor outcome with the highest incidence of both 30 and 90-day mortality of 
all liver resections as well as poor long-term survival due to a high frequency of R1 
resections and vascular invasion leading to early disease recurrence (53, 54). However, data 
on long-term outcome are rare and based on single-center reports (2, 55, 56) or data 
originating from certain medical registers (4). On the other hand, outcome for patients with 
colorectal liver metastasis (CRLM) has improved significantly over the last decades. From 
the first reports of the beneficial effect of resection for CRLM in the 1980´s and 90´s (1, 57, 
58) paradigms have been shifted many times. Today, patients with CRLM are potentially 
curable due to improved chemotherapy, re-resection and the introduction of other treatment 
modalities like local ablation techniques (e.g., radio-frequency ablation) (59-61). Even 
initially un-resectable patients have today, after successful downstaging by neo-adjuvant 
chemotherapy, the chance to undergo hepatectomy with curative intent (62, 63). A recently 
published score-system gained a good prognostic value in predicting the individual risk after 
hepatectomy for initially un-resectable liver metastasis and could demonstrate a good long-
term outcome for a certain group of patients (64). However, in general, little is known about 
the short- and long-term outcome of these patients in a population based setting. 
2.2.1 Prediction of complications/outcome after hepatectomy 
Regarding patient outcome after hepatectomy, it is important to differentiate between 3 
contributing causes with potentially influence on the results: 1. the underlying disease (e.g., 
cancer), 2. the medical background of the patient and 3. complications related to the treatment 
(hepatectomy). In order to stratify patients at risk for postoperative complications, several risk 
scores have been developed. Breitenstein et al. developed a risk score to predict severe 
complications following liver resection according to the Clavien-Dindo classification, based 
on American Society of Anesthesiologists category, transaminases levels (aspartate 
aminotransferase), extent of liver resection (>3 vs <3 segments), and the need for an 
additional hepaticojejunostomy or colon resection (65). In a systematic review, Yu et al.. 
screened 34 articles evaluating the predictive value of different scores in predicting 
postoperative complications and outcome (66). However, many scoring systems lack a solid 
validation. Therefore, the power of prediction on an individual level remains unclear. This 
might be a reason why preoperative risk scores have not been applied broadly in clinical 
practice. 
2.3 LIVER REGENERATION AFTER PARTIAL HEPATECTOMY 
Liver regeneration after partial hepatectomy is one of the most complex processes in the 
human body and extensively studied (67-69). The loss of liver tissue ignites a complex 
process in order to recuperate the original size of the liver (69). A large amount of key players 
contributing to this have been identified, including cytokines like IL-6 (70) or HGF (41), 
neurotransmitters like Serotonin (71), cellular factors like beta1-integrin (72) or hormones 
and their receptors like Insulin (73). Loss of these factors unavoidably alters or impairs liver 
regeneration after hepatectomy. Not only the expression and presence of all these factors, but 
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even the timely coordination of regeneration is considered to be of crucial importance in 
order to re-establish functional liver parenchyma. This is of special importance, as 
contributing liver and stem cells recovering at different time points after hepatectomy and 
disturbance have been identified as a cause of PHLF, too (67, 69). Liver regeneration is 
initiated immediately after completed hepatectomy, with a massive change of gene 
expression in hepatocytes (74). This induces amongst others HGF release, and up to 95% of 
resting hepatocytes start with the cell cycle by entering mitosis (40). Subsequently, the 
extracellular matrix along with blood vessels and bile ducts are reestablished (41, 75). Liver 
regeneration will be terminated when the liver has achieved a size large enough to provide 
homeostasis, a process described by Michalopoulos et al. as “hepatostat” (69). Disturbance of 
liver regeneration or removal of too much liver tissue might induce overshooting hepatocyte 
proliferation, leading to dysfunctional hepatocyte clusters, intra-cellular cholestasis, apoptosis 
and prolonged inflammation (76). Accordingly, a deceleration of liver regeneration after 
massive hepatectomy in rats has shown to positively influence recovery of both hepatic 
parenchyma and function (77). Nevertheless, the majority of data originates from animal 
studies in rodents; models to obtain equivalent knowledge in humans are living-donor 
hepatectomy (78, 79) or the ALPPS procedure (80, 81). However, as liver regeneration in 
humans differ from rodents, many questions remain unanswered. 
2.4 POST-HEPATECTOMY LIVER FAILURE  
Post-hepatectomy liver failure (PHLF) is a serious complication after hepatectomy. The main 
reason is a “small for size” situation of remaining liver tissue after extensive resection in 
relation to underlying quality of liver parenchyma (13, 20). Despite its potentially fatal 
impact on patient outcome, many aspects regarding PHLF are still poorly understood. Firstly, 
there are large differences regarding the incidence of PHLF in the literature. Related numbers 
range from 0.7% - 9.1% according to a review article by van den Broeck et al. (14). This 
trend was confirmed by a single-center analysis were the overall incidence of PHLF was 
found to be 9% according to the International Study Group of Liver Surgery (ISGLS) criteria 
(82). Another study found, when using the “50:50” and “peak bilirubin” criteria, an incidence 
of PHLF of 7% in patients with colorectal liver metastasis (83). The two most recent 
multicenter studies confirmed the incidence of PHLF between 5% and 9% (17, 18). However, 
those data are exclusively originating from tertiary hospitals. Furthermore, no population-
based data on the incidence and risk factors for PHLF are available. In order to be able to 
offer liver resection as a potential curative treatment even to borderline resectable patients, an 
effective treatment of PHLF would be of great value. In fact, treatment options have, despite 
intensive research, not improved substantially over the last decades (84). Recent 
recommendations are mainly based on treatment algorithms for acute liver failure and aim to 
prevent further liver damage by draining bile leakage and abscesses, treat infections, secure 
enteral nutrition and the avoidance of liver-toxic drugs (85, 86).  
Thus, enormous efforts are undertaken to avoid PHLF. Pre-operative volumetric 
measurement is a standard procedure in today’s expert centers to accurately determine the 
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FLR (87-89). In addition, there are several other preoperative tests to assess the individual 
hepatic functional capacity of every individual patient, in particular metabolic tests like the 
Indocyanin-green (ICG) test (90, 91), the LIMAX test (92) or radiology-based tests like 
hepatocyte-specific scintigraphy (93) or segmental magnetic resonance imaging, a rather new 
but highly promising technique (94, 95). Unfortunately, none of these tests can predict 
exactly how much liver volume is safe to resect in the individual patient as many other 
factors contribute to the functional hepatic reserve, like the presence of steatosis (96), 
cirrhosis (97) or parenchymal changes following chemotherapy like the "Sinusoidal 
Obstruction Syndrome" after oxaliplatin (98) or the "Chemo-Associated Steato-Hepatitis" 
after irinotecan (99). However, recommendations have been established and in our center, we 
accept today up to 80% resection for completely unharmed liver tissue, up to 70% in patients 
after chemotherapy and maximum of 60% in patients with cirrhosis. In patients with 
cirrhosis, portal hypertension and an ICG retention rate at 15 min (RR15) >20% are 
considered to be contra-indications for hepatectomy. However, despite this pre-operative 
workup it still remains difficult to completely avoid certain risk factors and thereby PHLF. 
2.4.1 Definitions of PHLF 
Another important problem to address is the need for a standardized definition of PHLF. A 
recent review by Lafaro et al. discussed several definitions proposed in the literature (84). 
Probably, the most commonly used definition is represented by the “50:50 rule” or also called 
“Balzan criteria”, a predictive score using a combination of bilirubin and Quick value to 
predict the individual mortality risk on postoperative day 5 (100). The cut-offs predicting a 
mortality risk >50% (bilirubin >50 µmol/l and Prothrombin time (Quick) <50%) were 
initially defined according to a retrospective single-center experience and could be confirmed 
in a later prospective study (101). In addition, Mullen et al. found in a large single-center 
cohort a peak-bilirubin >7 mg/dl to be highly predictive for mortality related to hepatectomy. 
The ISGLS made the most recent attempt to define PHLF. According to a consensus 
decision, PHLF is graded into 3 different severities, A, B and C. Grade A is defined by 
deviating liver values on POD 5 but otherwise normal clinical course. In contrast, patients are 
classified Grade B PHLF if they deviate from a normal course but do not require invasive 
treatment and finally Grade C patients who do require invasive treatment (102). This 
definition was evaluated in a retrospective single-center analysis that showed a significant 
increase in mortality from 2% in patients with Grade A PHLF up to 44% in patients with 
Grade C PHLF (82). However, studies still use several definitions making it difficult to 
compare results in the literature. 
2.4.2 Risk factors and Pathophysiology of PHLF 
The pathophysiology of PHLF differs considerably from pathophysiology in patients with 
acute (103) or acute-on-chronic (104) liver failure. After major hepatectomy, several changes 
in liver-specific blood samples, metabolism, the coagulation system, immune function and 
hepatic blood flow occur, varying dependent on the extent of resection (105). Most of them 
recover within one week from hepatectomy and more details are given above (chapter 2.3). 
 6 
Several key factors are contributing to the pathophysiology of PHLF and they can be divided 
into pre-, peri- and postoperative factors. Pre-operatively, the quality of underlying liver 
parenchyma (e.g., cirrhosis) has been identified as a crucial risk factor (97). Additionally, 
neo-adjuvant chemotherapy with oxaliplatin may induce the “sinusoidal obstruction 
syndrome", a veno-occlusive disease of the liver leading to necrosis, congestion and partially 
cholestasis (98, 106). Another well-described effect of chemo-associated toxicity is the 
development of "Chemo-Associated Steato-Hepatitis" after Irinotecan (99). Intra-operatively, 
there are two major risk factors for the development of PHLF; massive hemorrhage leading to 
hypotension and requiring blood transfusion, subsequently inducing ischemia-related damage 
to liver tissue (16, 20, 107). Another contributing factor is the ischemia reperfusion injury 
after inflow obstruction during hepatectomy, a phenomenon well known from liver 
transplantation (108). After hepatectomy in pigs, it was shown that nitric oxide contributes to 
increased cell death in the liver after warm ischemia induced by Pringles maneuver (109). 
Postoperatively, the so-called small-for size situation along with portal hypertension has been 
identified as a reason for increased necrosis and Kupfer-cell dysfunction (110, 111), thus 
contributing to the development of PHLF. Even though the liver is regenerating, there is a 
prolonged sensitivity to factors influencing liver volume restoration, like sepsis or 
postoperative hemorrhage and patients frequently die in a combined picture of PHLF and 
other severe complications and not of PHLF alone (107). 
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2.5 MOLECULAR ADSORBENT RECIRCULATING SYSTEM 
In the early 1990´s, a promising treatment option emerged for patients suffering from acute or 
acute-on-chronic liver failure with the development of extracorporeal liver support therapy 
(112). In 1993, Stange et al published a methodical description of the removal of Albumin 
bound toxins against a recycled Albumin solution (113). In theory, this should enable 
treatment possibilities with greater detoxification capacity than, e.g. hemofiltration alone 
combined with much less side effects than, e.g. plasma exchange (114). This system was then 
further developed and became clinically available as the Molecular Adsorbent Recirculating 
System (MARS), distributed initially by Teraklin AG, Rostock, Germany (Figure 1). Initial 
clinical results in patients with ALF, AoCLF and primary non-function after orthotopic 
liver transplantation showed promising results (115) and the MARS system became the 
most popular and most intensively studied device amongst all liver support systems to date. 
Figure 1. MARS monitor (Teraklin AG, Rostock, Germany) 
 
(with permission of Matthias Löhr) 
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2.5.1 Technical aspects of MARS 
MARS consists of a closed-loop with Albumin containing a dialysate circuit driven by an 
additional, standard hemodialysis machine (e.g., Prismaflex, Fresenius). The purification of 
the blood is achieved via a low-flow-dialyzer (MARS FLUX) and the dialysate is then 
recycled over an uncoated Charcoal column and an Anion exchanger column (Figure 2). 
Figure 2. The Molecular Adsorbent Recirculating System (MARS) 
 
 
(with permission of Matthias Löhr) 
Of all parts, the MARS Flux Dialysator could be considered as the most important element of 
the MARS system. In a pioneering work, Stange and Mitzner published their results in 1996, 
using a hybrid membrane consisting of a highly permeable hollow fiber (Figure 3) in 
combination with biologically attached transport proteins (Albumin), enabling selective 
transport of molecules between patients’ blood and the dialysate (116). By using this 
membrane, the MARS device is able to remove both water-soluble, and Albumin-bound 
toxins. The Albumin in the closed dialysate loop is then recycled over a charcoal adsorber 
together with an anion exchanger allowing to last one MARS session up to 24 hours until the 
filter system has to be changed (117). 
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Figure 3. Cross-section of a hollow-fibre of the MARS-Flux filter 
 
 
(with permission of Matthias Löhr) 
 
2.5.2 Clinical experience with MARS 
In clinical studies, MARS has shown a potential benefit for patients with acute (ALF) or 
acute-on-chronic liver failure (AoCLF) by stabilizing hemodynamic parameters with ensuing 
improvement of liver and kidney functions (118-120). Clinical improvement was also 
observed in patients with hepato-renal syndrome or critical-ill patients with concomitant liver 
failure (121, 122). Despite one prospective controlled trial suggested an improved 30-day 
survival after MARS treatment in patients having an acute deterioration superimposed on 
chronic liver failure (123), there is until today no RCT that could demonstrate a statistically 
significant survival benefit related to MARS treatment, neither in patients with acute-on-
chronic liver failure (124) nor in patients with acute liver failure (125).  
2.5.3 MARS in PHLF 
The use of MARS in the PHLF situation is based on the hypothesis, that extracorporeal liver 
support might disburden liver function from detoxification along with liver-toxic metabolites, 
thus facilitating recovery after hepatectomy. However, only a few single-center reports have 
been published describing the experiences with MARS treatment solely for PHLF. Those 
reports contain a small number of patients, present heterogeneous treatment groups and all 
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are lacking standardized treatment protocols. The outcome was poor with few if any 
surviving patients (119, 126-129). Probably due to the disappointing results, since the early 
2000´s there was no attempt made to evaluate the potentially beneficial effects of MARS in 
PHLF in a systematic way. Thus, based on the currently available literature, it is difficult to 
draw any conclusions about feasibility, safety, and efficacy of MARS treatment in patients 
with PHLF. 
2.5.4 Potential effect of MARS on liver regeneration after hepatectomy 
In detail, there are several effects of MARS treatment, observed when treating patients with 
acute or acute-on-chronic liver failure, which might be beneficial even in the PHLF situation. 
Firstly, MARS has proved to a certain degree to be effective in removal of Albumin-bound 
toxins (130, 131) and to improve the redox state of Albumin (131, 132). Thus, a reduced 
toxin-load in the recovering liver might support liver function in a way that could facilitate 
liver regeneration. Even portal hypertension after partial hepatectomy has been identified as a 
highly prognostic risk factor for the development of PHLF (110). As observed in patients 
with acute on chronic liver failure, MARS has a potential to decrease portal pressure, which 
could enhance the chance for a successful regeneration of the liver remnant (133). A major 
impact on liver regeneration might emanate from a possible influence on plasma levels of 
cytokines, as one study observed a clear correlation between liver volume increase 14 days 
postoperatively and plasma concentration of hepatocyte-growth factor (HGF) (134). In 
accordance, in one retrospective study by Donati et al., an increase of HGF under MARS 
treatment was observed (135), which might contribute to enhanced liver regeneration, too. On 
the other hand, it was shown in an animal model with a 90% partial hepatectomy, that a 
deceleration of regeneration by blocking key pathways (MEK/ERK) has led to improved 
outcome due to a better synchronization of the different liver cells under recovery (77). IL-6 
is known as a key promoter of liver regeneration (70, 136). In clinical studies, it could be 
demonstrated that MARS has the potential to remove IL-6 from plasma (25). Potentially, a 
decrease of IL-6 plasma concentration might contribute to a more synchronized liver 
regeneration after hepatectomy, too, thus avoiding impairment of liver function and the 
development of persistent PHLF. 
In summary, MARS could offer many beneficial effects for patients suffering from PHLF 
and related clinical effects should be further evaluated in prospective, controlled trials. 
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3 AIMS 
 
The aims of this thesis were: 
 
I. To investigate outcome after hepatectomy in Sweden in a population-based 
setting 
 
 
II. To evaluate the impact of PHLF on short-term mortality following hepatectomy 
in a population-based setting 
 
 
III. To retrospectively analyse the experience with MARS for treatment of PHLF and 
to critically review the available literature 
 
 
IV. To prospectively evaluate safety and feasibility of early MARS treatment in 
patients with PHLF according to an intensified treatment protocol 
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4 METHODS 
4.1 PAPER I 
4.1.1 Study design 
The study was designed as a retrospective, population-based register study in order to 
evaluate mortality and long-term outcome following hepatectomy in Sweden between 2002 
and 2011.  
4.1.2 Patients 
In order to identify the study population and to obtain the relevant data the Swedish in-
hospital registry, the national cancer registry, the “causes of death” registry and the registry of 
domestic and international relocations were used. Patients were identified in the Swedish in-
hospital registry based on procedure specific codes for hepatectomy (the Tenth Revision of 
the International Classification of Diseases and Procedures, ICD10; JJB00, JJB10, JJB20, 
JJB30, JJB40, JB50, JJB53, JJB60, JJB71, and JJB96) and then linked to the other registries 
using patients personal national registration number in order to obtain patient related data. 
The methods and registries used were described elsewhere (137, 138). 
4.1.3 Ethics 
The study was approved by the regional ethical board in Stockholm (DN 2010/1872-31/2). 
4.1.4 Statistical analysis 
Data were stratified in order to allow for risk factor analysis with implication for short-term 
mortality and long-term survival. Liver biopsies, ablations, and de-roofing of liver cysts were 
not considered in the analysis. Re-do resections were calculated as new event. Means ± 
standard deviations were computed for continuous variables, proportions for categorical 
variables. Long-term survival following hepatectomy was assessed by the Kaplan-Meier 
method. Cox proportional hazard ratios (HRs) with 95% confidence intervals (CI) were used 
for univariable and multivariable analysis of risk factors/hazard association; Age, sex, 
comorbidity, extent of resection, diagnosis and hospital category were used in the regression 
model. Introducing the variables stepwise into the multivariable regression model tested 
potential confounding effects. P values <0.05 were considered to be statistically significant. 
For statistical analyses, SPSS Version 20 for Windows was used (SPSS, Inc., Chicago, IL). 
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4.2 PAPER II 
4.2.1 Study design 
The study was designed as a retrospective, population-based register study in order to 
evaluate the impact of PHLF on 90-day mortality following hepatectomy in Sweden between 
2005 and 2009 
4.2.2 Patients 
Patient selection was done likewise paper I apart from the following changes: 
Study time was set from the 1st of January 2005 to 31st of December 2009. Patients with 
ICD10 procedure code for hepatectomy were identified in the Swedish in-hospital registry 
and correlated to other registries in accordance to Study I. These patients and, in addition, 
local hospital registries were used in order to identify patients positive for 90-day mortality 
following hepatectomy. As 90% of all liver surgery is performed at University hospitals, 
therefore data acquisition was exclusively focused on these 7 hospitals. For those patients 
who were identified, additional data regarding pre-, per- and postoperative course were 
obtained from local patient journal systems. The obtained data are available at the local 
hospital registries only and cannot be made available for the entire population.  
4.2.3 Ethics 
The study was approved by the regional ethical board in Stockholm and covered by the same 
application and approval as Study I (DN 2010/1872-31/2). 
4.2.4 Statistical analysis 
Data were calculated as means ± standard deviations for continuous variables, and 
proportions for categorical variables. In order to verify the population-based approach, the 
entire background cohort identified in the in-hospital registry was compared with those 
positive for 90-day mortality identified in local hospital registries. Patients positive for 90-
day mortality were then analyzed, divided into a PHLF and no-PHLF group. Primary PHLF 
was defined by the 50:50 criteria. Secondary PHLF was defined as liver failure occurring in 
the later postoperative course secondarily to complications. Chi-Square and Fisher´s Exact 
Test were used to compare proportions where appropriate and P-values <0.05 were 
considered to be statistically significant. Statistical analyses were performed using SPSS 
Version 20 for Windows (SPSS, Inc., Chicago, IL).  
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4.3 PAPER III 
4.3.1 Study design 
The study was designed as a retrospective cohort study including all patients who were 
treated with MARS due to PHLF a two major HBP centers, Karolinska, Stockholm and 
Hospital Clinic, Barcelona between 1st of November 2003 and 30th of November 2012. 
4.3.2 Patients 
Patients were identified in local hospital databases and relevant data was obtained 
retrospectively from electronic patient charts in the in-hospital patient management system. 
Patients were subjected to hepatectomy in one of the participating centers and developed 
PHLF due to various reasons. Patients who were treated with MARS with PHLF as indication 
were included and evaluated. Primary PHLF was defined according to the 50:50 criteria. 
Secondary PHLF was defined as PHLF occurring as result of liver failure associated with 
severe postoperative complications such as bleeding, bile leakage, sepsis or multiorgan 
failure due to, for example, cardiac infarction or pulmonary embolism. 
4.3.3 Ethics 
The study was approved by the regional ethical board in Stockholm and covered by the same 
application and approval as Study I and II (DN 2010/1872-31/2). 
4.3.4 MARS treatment 
MARS treatment was performed via a double lumen central vein catheter. A PRISMA flex 
machine (PRISMA, Gambro, Lund, Sweden) was connected to the MARS system in the first 
four patients in Stockholm and in all patients in Barcelona, whereas a MULTIFILTRATE 
(Fresenius Medical Care AG, Bad Homburg, Germany) system was used in the latter four 
Stockholm patients. Anticoagulation was achieved whether with systemic heparin in non-
coagulopathic patients or local anticoagulation with citrate in all Stockholm patients. Every 
MARS session was planned to last a minimum of 6 hours. 
4.3.5 Statistical analysis 
Statistical analysis was performed using JMP (Version 5.1.2). The results are reported as 
mean + SD, median (ranges) or n (%). Students t-test was used when appropriate and p-
values <0.05 were considered significant.
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4.4 PAPER IV  
4.4.1 Study design 
The study was designed as a prospective phase I safety and feasibility study in order to assess 
a novel MARS treatment protocol in patients with PHLF. 
4.4.2 Patients 
All patients being subjected to major or extended hepatectomy from 1st of December 2012 
onwards were eligible for enrolment. According to the study protocol, patients were screened 
for clinical and laboratory signs of PHLF until the 4th postoperative day. If patients fulfilled 
the inclusion criteria, mainly the 50:50 criteria as a definition for primary PHLF, patients 
were offered study inclusion on the 5th postoperative day. In total, 14 patients met the 
inclusion criteria and 10 patients were finally included in the study until 31st of May 2015 and 
treated according to the study protocol. Exclusion criteria were age >80 years, uncontrolled 
bleeding or sepsis, any relevant and untreated surgical complication (such as mechanical bile 
duct obstruction, clotting of the hepatic artery, or portal vein thrombosis) and platelet count of  
<20 x 109/L. Patients with secondary PHLF (caused by any postoperative complication 
leading to PHLF later than POD 5) were not included in the study. 
4.4.3 Ethics 
The study was approved by the regional ethical board in Stockholm (DN 2013/149-31/2). 
4.4.4 MARS and ICU treatment 
According to the study protocol, MARS treatment was initiated between POD 5-7 in all 
patients. A minimum of 5 treatment cycles had to be completed within 8 days from the first 
MARS treatment. At persisting liver failure (elevated liver-specific blood samples) a 
maximum of 7 treatments were applied. MARS cycles were considered sufficient after a 
minimum of 6 h continuous treatment. Due to technical reasons, MARS treatment had to be 
performed at the local intensive care unit. There, MARS treatment was done via a double 
lumen catheter inserted into the internal jugular or femoral vein. A continuous renal 
replacement therapy (MultiFiltrate; Fresenius Medical Care AG, Bad Homburg, Germany) 
system was used to run the MARS monitor (Baxter, Lund, Sweden). The blood flow on the 
MultiFiltrate machine was adjusted to 90-150 mL/minute, and the albumin flow on the 
MARS monitor was set to 150 mL/minute. Dialysate and replacement fluid flow were set to 
receive a renal dialysis dose of 35 mL/kg/hour. Anticoagulation of the MARS circuit was 
done by local anticoagulation with citrate as described before (139). Intensive care unit (ICU) 
treatment was standardized prior to study onset in accordance with the guidelines for 
treatment of acute liver failure, including renal hemodialysis (continuous veno-venous 
hemofiltration) along with MARS treatment, mechanical ventilation, drainage of fluid 
collections, directed treatment with antibiotics and antifungals, and parenteral nutrition if 
needed (14). 
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4.4.5 Assessment of safety, feasibility, and efficacy of MARS treatment 
In order to assess primary safety outcomes of early MARS treatment we evaluated the 
following variables:  
1. Bleeding complication and the need for blood transfusions 
2. Platelet count (termination of MARS or transfusion below 20x109/L) 
3. Severe electrolyte or acid-base derangements deemed secondary to local citrate 
    anticoagulation of the MARS circuit resulting in early termination of MARS treatment  
Feasibility was defined by the number of screened patients eligible for study inclusion related 
to those who finally have been included and treated according to the study protocol. In 
addition, we assessed drop-out of patients due to other than safety reasons (logistical or 
technical reasons). Efficacy was assessed by relevant blood samples prior to and after every 
single MARS session and at defined time points in the follow up (until demission, POD 60 
and 90, if possible). The Model for End-Stage Liver Disease (MELD) score (140) was 
calculated in each patient before and after MARS treatment. Encephalopathy was graded 
according to the West Haven criteria (141). Standard vital signs as blood pressure, heart rate, 
and oxygen saturation were monitored accordingly to ICU standard. In order to detect 
adverse events, clinical investigation of the patient was performed before and after each 
MARS session. Clinically significant complications were considered as an adverse event 
(the adverse event changed patient management, the patient required additional hospital 
care, the patient become permanently disabled, or the adverse event was considered to be 
life- threatening).  
4.4.6 Statistical analysis 
Data generated before study inclusion on POD 5 were collected retrospectively from the 
individual in-hospital patient files. From POD 5 onwards, data were collected prospectively. 
Categorical data were expressed as frequencies with percentages. Continuous variables are 
displayed as medians with interquartile range (IQR). The Wilcoxon signed rank test was 
performed to assess paired nonparametric data (blood samples and MELD score), and the 
significance level was set at p < 0.05. One patient (patient number 8) was considered to be an 
outlier and was excluded from statistical analysis. Statistical analysis was performed using 
SPSS software version 24.0.0.0.
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5 RESULTS  
5.1 PAPER I 
During observation time, a total of 4 460 (2 381 (53.4%) female, 2 079 (46.6%) male) 
hepatectomies were performed. Median age was 64 and 374 patients were operated two or more 
times. The number of patients who underwent hepatectomies in university compared to non-
university hospitals significantly changed over the study period. Thus, the incidence of liver 
resections increased from 2.5 per 100 000 inhabitants in 2002, to 8.1 per 100 000 inhabitants in 
2011. Comparing the first with the second 5-year period, the number of liver resections at non-
university hospitals decreased slightly from 336 to 312/5 years. At the same time, the number of 
hepatectomies performed at university hospitals increased from 1283 to 2529/5 years. In regards 
to the extent of resection, there was an increase from n=1 013 to n=1 832 in minor resections, 
from n=479 to n=791 in major resections and from n=127 to n=218 in extended resections, 
respectively. The vast majority of major and extended hepatectomies were done at university 
hospitals (96% years 2002-2006, 99% 2007-2011). Major and extended resections showed a 
significantly higher mortality risk compared to minor resections (Figure 1). With no change 
over the entire study period, for minor resections, the median postoperative hospital stay was 9 
days, after major resection 11 days and after extended resection 13 days.  For all hepatectomies, 
30- and 90-day mortality were 1.8 and 3.1%, respectively, with no significant change over the 
study period. After stratification for the extent of hepatectomy, we found significant differences 
in 30- and 90 mortality (Table 1). Comparing non-university with university hospitals, a 
significant difference in regards of 30- and 90-day mortality was found (30- and 90-day 
mortality in non-university hospitals: 3.8 and 6.6%; in university hospitals: 1.6 and 2.8%, 
p<0.001). The corresponding Kaplan-Meier estimation of survival following hepatectomy is 
displayed in Figure 2. In all patients, indications for hepatectomy were liver metastasis 
(n=2 644; 59%), HCC (n=393; 9%), GBC (n=254; 6%), ICC (n=129; 3%), and ECC (n=76, 
2;%).  In 10% of all cases, a diagnosis other/unclear was applied (n=452), in 2.5% bowel cancer 
(without “metastasis”, n=110), in 2% other liver malignancies (n=61) and 8% had a benign 
diagnosis (n=341). 5-year overall survival was 50% for patients with “liver metastasis”, 40% for 
HCC, 38% for GBC, 30% for ICC and 20% for ECC. The related Kaplan-Meier estimation is 
displayed in Figure 4.Re-resections were mainly performed in patients with diagnosis liver 
metastasis (78%) and resulted in a significant improvement of long-term outcome (Figure 5). 
Uni- and multivariable risk factor analysis revealed several significant risk factors for long-term 
survival after hepatectomy (Table 2). Age, comorbidity, male gender and hepatectomy 
performed in non-university hospitals showed to increase mortality risk significantly. University 
and non-university hospitals were considered to be equal with high and low volume hospitals 
and therefore excluded from multivariable analysis (due to co-linearity). In addition, diagnosis 
of ICC, ECC, and GBC were also recognized as independent risk factors for death, defining 
diagnosis “liver metastasis” as the baseline. Finally, long-term survival was impaired in patients 
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operated at non-university hospitals compared to those who underwent surgery at university 
hospitals (p<0.001).  
 
Table 1. Postoperative 30- and 90-day mortality specified for the Extent of Liver resection 
            
            
                Mortality %     
Extent of resection n 30 days     90 days     
            
            
Minor resections 2845 (63,8%) 1,4 2,3     
Major resections 1271 (28,5%) 2,1 3,2     
Extended resections 344 (7,7%) 4,3 7,5     
            
            
Minor resections (< 2 Couinaud segments), Major resection (3-4 Couinaud segments), 
Extended resection (> 4 Couinaud segments)       
            
 
Figure 1. Kaplan-Meier survival estimates for minor, major and extended hepatectomy 
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Table 2. Results of uni- and multivariable (Cox) regression analysis of risk factors for mortality (long-
term survival) 
           
  Univariable analysis     Multivariable analysis 
            
  HR (95% CI) p   HR (95% CI) p 
Demography           
  Age ≤54 y 1.00     1.00   
  Age 55-63 y 1.39 (1.19-1.61) <0.001   1.16 (0.99-1.35) n.s 
  Age 64-71 y 1.90 (1.65-2.20) <0.001   1.55 (1.34-1.79) <0.001 
  Age ≥72 y 2.43 (2.11-2.80) <0.001   1.90 (1.64-2.22) <0.001 
  Female sex 1.00     1.00   
  Male sex 1.20 (1.09-1.32) <0.001   1.11 (1.01-1.22) <0.05 
Comorbidity           
  Charlson 0 1.00     1.00   
  Charlson 1-2 1.44 (1.30-1.59) <0.001   1.36 (1.22-1.50) <0.001 
  Charlson 3-4 1.90 (1.26-2.87) <0.001   1.83 (1.20-2.78) <0.05 
  Charlson ≥5 3.23 (1.90-5.47) <0.001   3.06 (1.80-5.21) <0.001 
Diagnosis           
  CRLM 1.00     1.00   
  HCC 1.23 (1.06-1.44) <0.05   1.16 (0.99-1.36) n.s. 
  ICC 1.78 (1.41-2.25) <0.001   1.76 (1.38-2.23) <0.001 
  ECC 2.21 (1.70-2.93) <0.001   2.15 (1.62-2.87) <0.001 
  GBC 1.42 (1.19-1.70) <0.001   1.53 (1.27-1.85) <0.001 
  CRC 0.97 (0.73-1.30) n.s.   0.71 (0.52-0.95) <0.05 
  Other malignancy 0.83 (0.55-1.26) n.s.   0.83 (0.55-1.26) n.s. 
  Benign 0.15 (0.10-0.22) <0.001   0.19 (0.13-0.28) <0.001 
  Other 0.68 (0.57-0.81) <0.001   0.74 (0.62-0.88) <0.05 
Study period           
  2002-2006 1.00         
  2007-2011 1.05 (0.95-1.16) n.s.       
Extent of hepatectomy           
  Minor  1.00     1.00   
  Major 1.24 (1.12-1.38) <0.001   1.18 (1.05-1.31) <0.05 
  Extended 1.64 (1.40-1.92) <0.001   1.10 (1.28-1.78) <0.001 
Hospital Volume           
  High volume 1.00         
  Low volume 1.17 (1.05-1.32) <0.05       
Hospital structure           
  University Hospital 1.00     1.00   
  Non-university Hospital 1.46 (1.26-1.69) <0.001   1.57 (1.35-1.83) <0.001 
Re-resection           
   No 1.00     1.00   
   Yes 0.40 (0.31-0.50) <0.001   0.44 (0.34-0.56) <0.001 
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HR, hazard ratio; 95% CI, 95% confidence Interval; CRLM, colorectal cancer liver metastasis; HCC, hepato-
cellular carcinoma; ICC, intra-hepatic cholangiocarcinoma; ECC, extra-hepatic cholangiocarcinoma; 
GBC, gallbladder cancer; CRC, diagnosis of colorectal cancer coded for liver resection but without diagnosis" 
metastasis"; other malignancy, other liver malignancies; other, other and unclear diagnosis 
            
 
Figure 2. Kaplan-Meier survival estimates for hepatectomies performed at university vs. non-
university hospitals 
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Figure 3. Kaplan-Meier survival estimates for different malign diagnosis 
 
Figure 4. Kaplan-Meier survival estimates for single vs re-resection for CRLM 
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5.2 PAPER II 
During 2005-2009, a total of 2461 liver resections were performed in 2241 patients (220 re-
resections) with an age of 61.6 (13.6) years (mean, std) in all Swedish hospitals. 1322 patients 
(53.7%) were male and 1490 patients (60.5%) underwent hepatectomy due to CRLM, 150 
(6.1%) due to HCC, 88 (3.5%) due to CCC, 129 (5.2%) due to GBC and 604 (24.5%) due to 
other or benign diagnosis. 2194 (89%) hepatectomies were performed in 1993 patients (201 re-
resections) at one of the seven university hospitals. Of these patients, 1546 (62.8%) were 
subjected to minor hepatectomy, 718 (29.2%) to major and 197 (8.0%) to extended liver 
resection. 267 liver resections were performed in non-university hospitals and 30-day mortality 
was 1.5% and 90-day mortality 3.0%. Overall 30- and 90- day mortality was 1.4% and 2.7%, 
respectively and did not differ from mortality observed in university hospitals (1.4% and 2.6%, 
respectively). All patients positive for 90-day mortality at non-University hospitals underwent 
minor resections only, two for metastasis and the remaining six concomitant to other 
procedures. According to the in-patient’s registry, we identified 56 patients who died within 90 
days from surgery in one of the seven university hospitals. In the local registries, we identified 
46 patients (80.7%) positive for 90-day mortality who were subjected to elective hepatectomy 
and thereby accessible for further data acquisition. Additional information regarding the study 
population, both the background population of liver resections and those positive for 90-day 
mortality, is shown in Table 1. In the group with 90-day mortality, there is a significant 
overrepresentation of male sex, severely ill patients (Charlson score 1 and > 2) , diagnosis of 
cholangiocarcinoma and gallbladder cancer as well as major and extended hepatectomy. 
Subdividing all patients with 90-day mortality in a PHLF and no-PHLF group, 19 patients 
(41%) were allocated to the PHLF group. Of those, 16 patients fulfilled the 50:50 criteria. The 
remaining 3 patients were allocated due to PHLF developed in the later course as a consequence 
of secondary complications. In all patients, PHLF was considered to be the main reason for 
death, whether alone or in combination with multi-organ failure. In the no-PHLF group, we 
allocated 27 patients (59%). Three, respectively two patients had elevated bilirubin or INR on 
POD 5 but no patient fulfilled the 50:50 criteria. These patients did not develop liver failure in 
the later course. Comparing the baseline characteristics in the PHLF and no-PHLF group, there 
were significantly greater proportions of patients with CCC (p=0.01) and after extended 
hepatectomy (p=0.019) in the PHLF group. On the other hand, in the no-PHLF group there 
were more patients after minor resections (p<0.001). Additional data is shown in Table 2. When 
comparing pre-operative variables, we could not identify any significant difference between the 
PHLF and no-PHLF group. Data are detailed in Table 3. Intra-operatively, we found a 
statistically significant higher proportion of patients with vascular reconstructions in the PHLF 
group (p=0.026). Other variables did not differ significantly and details are shown in Table 4. 
Analyzing a compilation of variables related to the postoperative course of patients, we found 
several significant differences in between the PHLF and no-PHLF group. Bilirubin > 50 µg/L 
and INR <1.5 were significantly more often found in the PHLF compared to the no-PHLF 
group on POD 3 already (p<0.001). In the postoperative course, even encephalopathy of any 
  25 
grade was found more frequently in the PHLF group than in the no-PHLF group (p<0.001). In 
contrast, transfusion of blood products was found more often in the no-PHLF group (p=0.036). 
No other significant differences were found and all postoperative variables are compiled in 
Table 5. 
 
Table 1.  Group of all liver resections in Sweden 2005-2009 compared with the 90-day 
mortality group  
CRLM, colorectal liver metastasis; HCC, hepato-cellular cancer; CCC, cholangiocarcinoma; GBC, 
gallbladder cancer; n.s., non-significant 
 
       Hepatectomies  90-day mortality  
N % N % p 
Total 2461  46   
Age ( mean, std) years 61.6 (13.6)  67.4 (8.1)  n.s. 
Male sex 1322 53.7 33 71.7 n.s. 
Comorbidity Charlson score 0 1671 67.9 10 21.7 <0.001 
                                                   1 700 28.4 26 56.5 <0.001 
                                                   ≥2 90 3.7 10 21.7 <0.001 
Diagnosis                                 CRLM 1490 60.5 22 47.8 n.s. 
                                                  HCC 150 6.1 3 6.5 n.s. 
                                                  CCC 88 3.5 10 21.7 <0.001 
                                                  GBC 129 5.2 11 23.9 <0.001 
                                                  Benign or other 604 24.5 16 34.8 n.s. 
Type of resection                   Minor 1546 62.8 16 34.8 <0.05 
                                                  Major 718 29.2 13 28.3 n.s. 
                                                  Extended 197 8.0 17 37.0 <0.05 
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Table 2. Data from medical charts on resected patients who died within 90 days at university 
hospitals 
 PHLF-group 
(N= 19) 
No-PHLF-group 
(N=27) 
p 
 N % N %  
Age (mean, std) years (67.5, 7.1)  (67.7, 8.7)  n.s 
Male sex 13 68.4 19 73.1 n.s 
Comorbidity      
                         Charlson 0 3 15.8 6 22.2 n.s 
                         Charlson 1 10 52.6 16 59.3 n.s 
                         Charlson ≥2 6 31.6 4 14.8 n.s 
Diagnosis         
                                     CRLM 7 36.8 14 53.8 n.s 
                                      HCC 2 10.5 1 3.8 n.s 
                                      CCC 8 42.1 2 7.7 =0.01* 
                                      GBC 2 10.5 9 34.6 n.s 
Type of resection         
                                  Minor 1 5.3 15 57.7 <0.001** 
                                  Major 9 47.4 7 26.9 n.s 
                                  Extended 9 47.4 4 15.4 =0.019** 
*Fisher’s exact test, **Chi-square test; n.s., non-significant; CRLM, colorectal liver metastasis; 
HCC, hepato-cellular cancer; CCC, cholangiocarcinoma; GBC, gallbladder cancer
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Table 3. Pre-operative data on PHLF and no-PHLF patients 
 PHLF-group 
(N=19) 
Non PHLF-group 
(N=27) 
p 
 N % N %  
BMI≥30 4 21 4 15 n.s 
Smoking 1 5 3 11 n.s 
Diabetes 6 32 3 11 n.s 
Hypertension 6 32 12 44 n.s 
Hepatitis 0 0 3 11 n.s 
ASA≥2 16 84 20 74 n.s 
Preoperative chemotherapy 3 16 5 18 n.s 
Cholestasis at time of surgery 7 37 5 19 n.s 
PVE 3 16 1 4 n.s 
BMI, body mass index; ASA, American Society of Anesthesiologists score; PVE, portal venous 
embolization; n.s., non-significant 
 
Table 4. Intra-operative data on PHLF and non PHLF patients 
 PHLF-group 
(N=19) 
Non PHLF-group 
(N=27) 
p 
 N % N %  
Pringle 7 37 10 37 n.s 
TVE 1 5 0 0 n.s 
Resection of extrahep bile ducts 8 42 6 22 n.s 
Vascular reconstruction 4 21 0 0 =0.026* 
Combination with other surgery 0 0 4 15 n.s 
Combination with ablation 0 0 4 15 n.s 
Operative bleeding>2000 ml 8 42 8 30 n.s 
*Fisher’s exact test; TVE, total vascular exclusion; extrahep, extra-hepatic; n.s., non-significant 
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Table 5. Postoperative data on PHLF and non PHLF patients 
 PHLF-group 
(N=19) 
Non PHLF-group 
(N=27) 
p 
 N % N %  
Cirrhosis 4 21 3 11 n.s 
Steatosis 4 21 10  n.s 
Fibrosis 5 26 3 11 n.s 
POD 3      
               Bilirubin≥50 µg/L  15 79 3 11 <0.001** 
               INR>1.5  15 79 1 4 <0.001** 
POD 5      
               Bilirubin≥50 µg/L 16 84 3 11 <0.001** 
               INR>1.5 16 84 2 7 <0.001** 
               Platelets<100x10(9)/L  5 26 2 7 n.s 
               Creatinine>120 µmol/L   7 37 3 11 n.s 
Postoperative transfusion 5 26 15 55 =0.036** 
Bile leakage 2 11 7 26 n.s 
Surgical intervention 5 26 10 37 n.s 
PTC/ERCP 2 11 2 7 n.s 
Infection 6 32 14 52 n.s 
Aspiration 1 5 3 11 n.s 
Portal thrombosis 5 26 1 4 n.s 
Encephalopathy 8 42 0 0 <0.001* 
*Fisher’s exact test, **Chi-square test; n.s., non-significant; POD, postoperative day; INR, 
international normalized ratio; PTC, percutaneous-transhepatic-cholangiography; ERCP, 
Endoscopic retrograde cholangiopancreatography 
 
 
5.3 PAPER III 
In total, 13 patients (5 Hospital Clinic, 8 Karolinska Huddinge) were identified and included 
in the analysis. 7 patients had CRLM, 5 had primary hepato-biliary malignancy and 1 patient 
had a neuroendocrine disorder, MEN 1. Additional demographic and clinical data is shown in 
Table 1. In order to distinguish between patients, they were categorized into primary and 
secondary PHLF. Primary PHLF was defined by the 50:50 criteria, and secondary PHLF was 
defined by liver dysfunction following postoperative complications in the later postoperative 
course. 
In the group with primary PHLF, we identified 9 patients fulfilling the 50:50 criteria (100). In 
these patients, treatment was initiated between POD 3 and 21 (median POD 8). A median of 
3 (range 2-6) MARS sessions were performed in each patient. In total, four out of nine 
patients (44%) survived 90-days postoperatively. Three of them were alive one year after 
surgery. Comparing surviving and non-surviving patients, we could not identify significant 
differences in regards to the point of time of treatment start or treatment intensity. However, 
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we observed a trend towards more frequent MARS treatment in the surviving group 
(Survivors, median 5, range 4-6; non-survivors, median 2, range 2-3). MARS did not result in 
significant changes in bilirubin, creatinine, ALAT, platelets or INR. The safety profile of 
MARS treatment was good with no complications directly related to MARS treatment. 
Four patients were allocated to the secondary PHLF group. In these patients, secondary 
PHLF occurred due to pulmonary embolism (POD 5) and a ruptured pseudo-aneurysm of the 
hepatic artery (POD 22) in patient 1. Patient 2 suffered from an acute bleeding from the 
hepatic artery on POD 11. Patient 3, firstly had an acute bleeding from a duodenal ulcer 
which was leading to a stroke, followed by rectal bleedings on POD 17, and in patient 4, 
there occurred a septic shock on POD 30 leading to secondary PHLF. 
In patients with secondary PHLF, MARS treatment was started later between POD 17 and 39 
(median POD 32). Overall, the four patients received 1-4 treatment cycles (median 2). None 
of the patients survived. 
Table 1. Demographic and clinical data of the study population 
 
m (male); f (female); KH, Karolinska University Hospital Huddinge, Stockholm; HC, 
Hospital Clinic, Barcelona; CRLM, colorectal cancer metastasis; CCC, cholangiocarcinoma; 
MEN, multiple endocrine neoplasia, HH, hemihepatectomy; POD, postoperative day. 
 
5.4 PAPER IV 
From December 1st 2012 to May 31st 2015, 206 patients underwent major/extended 
hepatectomy and were screened for the study at Karolinska University Hospital. Regarding 
feasibility, 10 out of 14 patients who fulfilled the inclusion criteria on POD 5 could be 
included in the study and treated according to the protocol (Figure 1). The study population 
consisted of six male and four female patients (median age of 69 years (range 49-77)).  
According to the main safety outcome measures, there were no severe complications or 
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mortality during or after MARS treatment. We observed no bleeding and there was no need 
to transfuse blood products due to MARS treatment. Electrolytes and acid-base balance were 
kept within safety limits by standard replacement therapy. Two patients experienced flow 
problems with the central line which had to be replaced twice. 
 However, in one patient (patient no. 8), we observed a severe increase of bilirubin (peak total 
bilirubin about 1000 micromol/L) along with a modest increase of INR (range between 2 and 
3). We could exclude mechanical bile duct obstruction by repeated radiology (CT, MR, and 
MRCP) and ERCP. Unfortunately, we could not identify a reason for this development 
despite repeated discussions with experts in the field. 
Figure 1. Study flow chart 
 
 
Indication for surgery was colorectal cancer liver metastases in 5 patients, perihilar 
cholangiocarcinoma in 4 patients and hepatocellular cancer in 1 patient. Additional 
demographic data is shown in Table 1.  
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In average, the mean preoperative FLR/BW ratio was 0.55 (IQR 0.25) and the mean 
standardized FLR 26.1% (IQR 11.3%). In two patients, portal venous embolization (PVE) 
was performed preoperatively and FLR-increased by 28% and 24%, respectively. In order to 
assess patients FLR postoperatively, calculations were done retrospectively on CT´s 
performed for clinical indications. This was the reason, why the investigations were done at 
different time points, making it difficult to compare the results. In all patients we observed an 
increase of FLR within 25 days from surgery. Completing information on volumetric 
measurements is displayed in Table 2.  
 
Two out of ten patients had severe postoperative complications (Clavien-Dindo > 3b); in one 
patient, re-operation was needed due to hemorrhage and in one patient ERCP was done in 
general anesthesia in order to achieve stenting of the common bile duct. More details 
regarding histopathology and intra-/postoperative complications can be found in Table 3.  
Table	1	Patient	characteristics	of	the	study	population
Patient Age Sex BMI Diabetes CVD Smoker Indikation Cx Surgery
0	=	no;	1	=	yes 0	=	no;	1	=	yes 0	=	no;	1	=	yes 0	=	no;	1	=	yes
1 71 m 24 0 0 0 CCC 0 Extended	right	hepatectomy
2 75 f 31 0 0 1 CRLM 1 Extended	right	hepatectomy
3 65 f 21 1 0 0 CCC 0 Extended	right	hepatectomy
4 68 m 23 0 1 0 CCC 0 Extended	right	hepatectomy
5 66 f 23 1 1 0 CCC 0 Extended	right	hepatectomy
6 77 f 20 0 0 0 CRLM 1 Right	hepatectomy	+	seg	1
7 72 m 25 0 1 0 HCC 0 Extended	right	hepatectomy
8 57 m 31 0 0 0 CRLM 1 Right	hepatectomy	+	local	seg	4
9 72 m 29 0 0 0 CRLM 0 Right	hepatectomy	+	local	seg	4
10 49 m 26 0 0 0 CRLM 1 Extended	right	hepatectomy
median	(IQR) 69,5	(10) 24,5	(7)
BMI	=	body	mass	index;	CVD	=	cardio-vascular	disease;	PVE	=	portalvein	embolisation;	m	=	male;	f	=	female;	CCC	=	cholangiocarcinoma;	
CRLM	=	colo-rectal	liver	metastasis;	HCC	=	hepatocellular	cancer;	Cx	=	neoadjuvant	chemotherapy;	seg	=	liver	segment;	
Table	2	Volumetric	measurements
Patient FLR	segments FLR	preop FLR/BW	 sFLR	preop Liver	dysfunction	** TELV	pre	op Specimen	weight Postop	CT Postop	volume Increase	postop
mL preop % 0	=	no;	1	=	yes (calculated) grams mL volume	mL/day
1 1-3 140 0.22 10.2 0 1371 1117 POD	94	 730 6.3
2 1-3 480 0.58 28.8 0 1665 1305 POD	23 897 18.1
3 1-3 190 0.33 14.9 0 1271 766 POD	25 804 24.6
4 2-3 250/320	* 0.45 20.4 1 1568 950 POD	12 803 40.3
5 1-3 290/360	* 0.62 28.8 1 1248 1295 POD	49 945 119
6 2-4 295 0.58 26.5 0 1114 726 POD	5 488 38.6
7 2-3 840 0.88 41.4 0 2028 1983 POD	5 1388 109.6
8 1-4 510 0.52 25.7 1 1983 1000 POD	24 1525 42.3
9 1-4 370 0.38 18.4 1 2011 1049 POD	15 910 36
10 1-3 535 0.61 28.3 1 1893 1320 POD	23 1084 23.9
*	pre/post	portal	venous	embolisation;	FLR	=	future	liver	remnant;	sFLR	=	standardized	future	liver	remnant;	BW	=	body	weight;	preop	=	preoperatively,	
postop	=	postoperatively;	TELV	=	total	estimated	liver	volume;	**	persistent	liver	dysfunction	on	POD	90;	CT	=	computed	tomography
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In all patients, MARS treatment was initiated within seven days from surgery.  Due to a lack 
of resources at the ICU, in two patients MARS treatment could not be performed 
continuously but had to be interrupted (for two and three days, respectively). This did not 
represent a protocol violation as all patients underwent at least five completed MARS 
sessions within eight days from the start of treatment. Clotting of the MARS filter occurred in 
one treatment cycle, and this MARS session was repeated with a new filter. Excluding patient 
no. 8 from statistical analysis, we observed a significant decrease of both bilirubin and INR 
under MARS treatment (bilirubin p = 0.042; INR p=0.023). On the other hand, there was no 
significant impact on creatinine, CRP, ammonia, platelets, and MELD score (Figure 2). Four 
patients showed signs of hepatic encephalopathy at time of ICU admittance (Westhaven 
grade II or higher). One of these patients developed respiratory failure and was put on 
mechanical ventilation. After three MARS cycles, the patient had improved substantially, and 
mechanical ventilation was terminated. The remaining three patients improved clinically as 
well, and no need for parenteral nutrition and mechanical ventilation occurred. Additional 
information on ICU and MARS treatment is given in Table 4. 
 
Outcome of the study population was no 60-day mortality and 1/10 (10%) 90-day mortality. 
Disease free one year survival was 50%. All patients recovered in terms of liver function 
Table	3	Histopathology	and	complications
Patient Pathology Inflammation Fibrosis Steatosis Specimen	weight Complication	intra-/postoperatively
grade grade grade grams
1 GBC,	T3	N1	R1 1 2 2 1117 Postop	bleeding,	re-op	POD	4
2 CRLM,	focal	R1 0 2 3 1305 HE
3 IG4	cholangitis 0 2 0 766 Bile	leakage,	conservative	treatment,	HE	
4 CCC,	T2b	N2	R1 1 1 1 950 Ascites,	sepsis	
5 GBC,	T3	N0	R1 1 3 0 1295 HE
6 CRLM,	focal	R1 0 1 2 726 HE,	systemic	infection
7 HCC,	T3b	V1	R0 1 2 2 1983 HE,	bile	leakage,	conservative	treatment
8 CRLM,	focal	R1 1 2 2 1000 Intra-op	injury	of	the	left	bileduct,	ERCP,	Stent
9 CRLM,	focal	R1 0 1 2 1049 None
10 CRLM,	focal	R1 0 1 1 1320 Intraop	bleeding,	ascites
	
GBC	=	gallbladder	cancer;	CRCm	=	colo-rectal	liver	metastasis;	CCC	=	cholangiocarcinoma;	HCC	=	hepato-cellular	cancer;	
HE	=	hepatic	encephalopathy	(Westhaven	grade	2	or	higher);	ERCP	=	endoscopic	retrograde	cholangio-pancreatography
Table	4	ICU	and	MARS	treatment
Patient SAPS	Score MELD	 MELD	 MARS		start MARS	end MARS	 MARS	pause CRRT/ Mechanical	
before	MARS after	MARS sessions days renal	failure ventilation
1 80 18 22 POD	7 POD	14 7	(4+3) 2 1 0
2 67 23 18 POD	6 POD	12 5 0 0 0
3 72 19 12 POD	5 POD	12 5 0 0 0
4 60 22 24 POD	7 POD	17 7	(3+4) 3 0 0
5 67 21 20 POD	6 POD	13 7 0 1 0
6 72 20 14 POD	6 POD	11 5 0 0 0
7 91 20 13 POD	5 POD	10 5 0 0 3	days
8 61 24 31 POD	7 POD	13 7 0 1 0
9 61 19 17 POD	6 POD	10 5 0 0 0
10 68 21 16 POD	7 POD	12 5 0 0 0
median	(IQR) 67,5	(13) 21	(5) 19	(9)
SAPS	=	simplified	acute	physiology	Score;	MELD	=	model	for	end-stage	liver	disease;	CRRT	=	continious	renal	replacement	therapy;
POD	=	post-operative	day
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parameters. All remaining four patients suffered of disease recurrence (perihilar 
cholangiocarcinoma in one and colorectal liver metastasis in three) and succumbed between 
POD 130 and 348. 3/4 showed signs of chronic liver dysfunction. Additional information on 
patient outcome is shown in Table 5. 
 
In a historical cohort of patients between January 2010 and November 2012, 248 patients 
were operated with major or extended hepatectomy. 11 patients (4.4%) met the 50:50 criteria 
on POD 5. 60- and 90-day mortality rates were 64% (7/11). Thus, we could validate the 
50:50 criteria in our institution as sound instrument in order to predict 60- and 90-day 
mortality. 
Table	5	Patient	outcome	and	survival
Patient Hospital	stay/days Bilirubin	POD	90 INR	POD	90 60-day	mortality 90-day	mortality Liver	dysfunction**
(until	1.	demission) mikromol/L 0	=	no;	1	=	yes 0	=	no;	1	=	yes 0	=	no;	1	=	yes
1 35 18 1.3 0 0 0
2 46 18 1 0 0 0
3 35 37 1.3 0 0 0
4 128 427 1.4 0 0 1
5 90 619 2.5 0 1 1
6 20 n.a. n.a. 0 0 0
7 39 353 1.2 0 0 1
8 46 380 1.8 0 0 1
9 24 38* 1.4* 0 0 1
10 30 24 1.5 0 0 0
median	(IQR) 37	(29) 195	(396) 1,4	(1,0)
POD	=	post	operative	day;	na	=	not	available;	*	=	on	POD	144;		**	=	liver	dysfunction	on	POD	90
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Figure 2. Blood samples before/after MARS treatment 
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6 DISCUSSION 
6.1 GENERAL DISCUSSION 
6.2 STUDY DESIGN 
6.2.1 Population-based register studies 
With increased centralization and specialization of cancer treatments, data on patient 
outcome, complications and survival often originate from highly specialized centers (6, 82, 
142, 143). Data obtained might be biased in many ways, by e.g., patient selection, higher 
quality of care at high volume centers, publication bias of poor vs. favorable results, etc. 
(144). Therefore, a transfer of results from single center experience on an entire population 
might not be suitable. To avoid this problem, population-based studies represent a unique 
methodological way in order to answer research questions. This approach implicates many 
favorable aspects, like the possibility to access a huge amount of already existing data at low 
costs leading to a high quality of scientific studies (145). However, even population-based 
evaluations suffer from several disadvantages. The intended variables may not be available, 
inappropriate registered or coded incorrectly leading to ambiguous results (146, 147).  Hence, 
a control for confounders might be difficult (148). Both, study I and II used population-based 
register data in order to answer the research questions. In previous studies, a good to very 
good data quality of the registries could be validated (149). In addition, for study II there was 
a usage of data from local hospital registries, too. Thus, study II might not be considered as 
completely population-based, as part of the data used were obtained from other than 
population-based registries. Thereby, the study might be seen as a combination of 2 different 
study types, a population-based register study and a retrospective chart review, which is 
discussed below. 
6.2.2 Retrospective chart review study 
Another study approach is represented by the retrospective chart review (RCR). When doing 
this kind of study, a sample of retrospectively collected data from already existing databases, 
e.g., hospital charts, is used in order to answer the research question (150).  However, several 
issues have to be discussed, addressing both advantages as well as limitations of this study 
design. An advantage is that RCR is a cheap and fast way to obtain relevant data and to 
answer research questions in order to guide the design of prospective studies (150).  
Limitations are numerous and extensively discussed be Vassar et al. (151). Most importantly,  
a lack of clearly defined study plans, misconduct in data registration and under-powering of 
the study sample might be mentioned. In this thesis, study III used a RCR design in order to 
answer the research question. Given the patient cohort that was investigated, under-powering 
was a major issue as MARS treatment in the PHLF situation was done in so few patients. 
Partially, we tried to minimize this limitation by conducting a multicenter study in order to 
broaden the study population. A related problem was represented by the heterogeneity of 
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patients in the treatment group, making it impossible to control for confounders with the 
identified number of patients.  
6.2.3 Prospective pilot study  
In study IV, we defined safety and feasibility as the primary outcome. In accordance, the 
study was designed as a phase I safety and feasibility study. This kind of study design is 
primarily known from pharmacological studies and phase I is analogs to “first in men”. Even 
though MARS was used in human beings before, the indication and especially the treatment 
protocol was not studied before, thus justifying this approach and definition. However, the 
study design could be described as a prospective pilot study, too. The purpose was to test an 
intensified treatment protocol at a different time point of the postoperative course, compared 
to earlier experience. Systematically obtained data was not available prior to this study. In 
order to validate our inclusion criteria and patient outcome, data of a historical patient cohort 
was used for analysis. The used study design implicates limitations in regards to statistical 
power of the results. However, given the very low incidence of the studied condition, there 
was no study design available being more suitable in order to test our research hypothesis, 
and, secondarily, making it possible to design a prospective randomized trial in the future 
based on the results from the pilot trial. 
6.3 STUDY RESULTS AND IMPLICATIONS FOR THE FUTURE 
6.3.1 Study I  
The present study found an overall low 30- and 90-day mortality compared to a previous 
study conducted in France (9). At the same time, the numbers of performed liver resections 
increased significantly in Sweden. However, this increase was restricted to university 
hospitals and reflects an ongoing, nationwide process of centralization, gathering certain 
cancer treatments at selected high volume centers, what in Sweden is equally to university 
hospitals. At the same time, our results demonstrated a much better short and long-term 
outcome of patients treated at university hospitals compared to non-university hospitals, an 
effect observed before (152) which further supports the centralization process. This effect 
was even seen for other tumor entities in the upper gastrointestinal area before, e.g., 
pancreatic or esophageal cancer (153, 154). This effect remained even after correction for 
several confounders. Interestingly, not even surgeon or hospital volume alone was identified 
as a significant risk factor in the meta-analysis of Brusselaers et al., analyzing 16 studies on 
esophagectomy due to cancer (153). In our study, another positive effect in respect to the 
long-term outcome was found for patients who were re-resected for CRLM. This represents 
off course a very selected group of patients, but, thus our results confirm earlier observations 
from single centers in a population-based setting (155-157) and support aggressive surgical 
strategies in case of localized cancer recurrence. A very important issue  identified by this 
study is the overall very low mortality following hepatectomy in Sweden. Comparing our 
results with the French study by Farge et al. (9), several differences can be identified. Firstly, 
Sweden has another case-mix with a lower number of cirrhosis patients subjected for 
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hepatectomy. As cirrhosis was identified as major risk factor for poor outcome after 
hepatectomy (20), this finding might contribute significantly to improved outcome in 
Sweden. Another remarkable aspect was seen in a much lower incidence of hepatectomy 
/inhabitant in Sweden compared to France. Whether this reflects a difference in the incidence 
of diseases treatable by liver surgery or is an expression for differences in patient selection, 
remains unclear. However, as France was from the very beginning a leading country in terms 
of development of liver surgery (30, 158, 159),  a more conservative patient selection and as a 
consequence, a more favorable patient outcome in Sweden, might be assumed. Regarding 
outcome in relation to the underlying diagnosis, our study confirmed earlier reports, with the 
best long-term survival for patients with CRLM and poorest outcome for primary biliary 
cancers (4, 7, 12).  
In the future, further centralization should be supported in order to decrease mortality related 
to primary biliary malignancies due to improved research and treatment strategies. Register- 
based studies should be repeated periodically in order to assure the quality of cancer 
treatments and to identify further needs for improvement. 
6.3.2 Study II  
Our study confirms that PHLF has to be considered as one of the main reasons for 
postoperative short-term mortality even in a population-based setting. As shown previously, 
specific risk factors significantly contribute to death in the PHLF group compared to those 
patients with 90-day mortality due to other reasons than PHLF.  
PHLF is considered a severe complication following hepatectomy with a frequently dismal 
outcome (84, 160). However, there are several remaining problems in the understanding and 
description of PHLF. The maybe most important limitation is found in the problem of 
defining PHLF as this massively influence the incidence of PHLF. In the year 2005, Balzan 
et al. were the first to publish a risk score, a combination of bilirubin value and INR on 
postoperative day, to predict in-hospital mortality following hepatectomy (100) and the 
accuracy of this so-called “Balzan” or “50:50” criteria was prospectively confirmed later on 
(101). However, several reports could not confirm the accuracy of the 50:50 criteria but 
proposed other variables in order to define PHLF and predict patient outcome. The most 
important ones are represented by the ISGLS criteria (102), the Mullen or “peak-bilirubin” 
criteria (15) and the Hyder score (161). Recent reports focused on validating especially the 
ISGLS criteria (17, 162), but on the other hand, even the “50:50” criteria, as well as the 
Mullen criteria, are still used in current publications (83, 163). In recent years, several 
reviews have summarized the available literature regarding PHLF and discussed important 
issues like definition and prevention, risk factor analysis, management and outcome of 
patients with PHLF (84, 160, 164, 165). Compared to the reviewed reports, our study 
provides several advantages. A major benefit is represented by the study design with a 
population-based approach, covering all hepatectomies in Sweden over a 5 year period. This 
is a unique methodology in the evaluation of PHLF and implicates improvement of data 
quality as they do not contain any selection bias compared to single center data (6, 82, 166). 
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Another advantage is represented by the large number of patients included in the study, which 
increases the statistical power of the results. As we have observed in a previous study, 
mortality following hepatectomy is lower in Sweden (167) compared to other population-
based data (9, 10). All University Hospitals in Sweden apply national, evidence-based 
guidelines for patient selection prior to surgery. However, patient mix/characteristics with a 
lower number of patients with, e.g. cirrhosis and a more conservative patient selection in 
regard to, e.g. age, might contribute to lower short-term mortality in Sweden. Despite this 
differences in terms of patient selection, even in the present study, PHLF contributes to or is 
the single cause in 40% of all deaths within 90 days from surgery. At non-university 
hospitals, we identified 8 patients positive for 90-day mortality. All of them were subjected to 
minor resections, and we considered this as a consequence of the ongoing process of 
centralization of major liver surgery to expert centers in Sweden. Thus, the case mix of non-
university hospitals is not representative anymore, as only minor resections are left and in 
consequence, the risk for PHLF as cause of death should be minimal at these hospitals. 
On the other hand, there are several limitations in the present study. Due to the retrospective 
study design, it might be assumed that the quality of the obtained data is not as good as 
compared to prospectively collected data and several variables had to be excluded from 
analysis due to this problem. Another issue could be seen in the period of time for the data 
collection, which was set from the year 2005 to 2009. However, data of this paper have been, 
as stated in the methods, partially published before (167). The first publication raised several 
scientific questions which we were able to address in the present study. In addition, from 
2009 onwards, there was a new registry, the national liver registry, introduced in Sweden. 
Data from this registry might be, after validation, available in the near future for a follow-up 
study of the present report. Another problem was the mismatch of cases positive for 90-day 
mortality in the Swedish Hospital Discharge Registry compared to local hospital registries. 
The most likely explanation might be incorrect coding in the Swedish Hospital Discharge 
Registry, or even more likely, liver resections have been performed by other specialties than 
liver units, e.g., trauma units, colorectal surgeons or urologists. Therefore, it might not have 
been possible to identify this cases in the local hospital registries, where only data on elective 
hepatectomies were available. As major and extended hepatectomies and thereby the risk for 
PHLF are more unlikely to be missed in this situation, there could be an underestimation of 
deaths due to other causes in our final patient population, and thus, the impact of PHLF could 
be overestimated for the whole population. Finally, due to the study design, we are not able to 
present the incidence of PHLF in the entire population as these data, mainly blood samples, 
are not available in the used nationwide registries.   
In summary, PHLF represents a major risk for short-term mortality and measures have to be 
taken to improve both, avoidance and treatment, of patients with PHLF. 
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6.3.3 Study III 
According to our experience, we found the use of MARS to be safe in the PHLF situation 
with a related short-term survival superior to previous reports.  
Since its introduction in 1993 (114), MARS has become the most popular one amongst all 
extracorporeal liver support devices. In several clinical studies, it was shown that MARS is a 
safe procedure, being able to significantly remove both protein-bound and water-soluble 
toxins along with an improvement of both kidney and liver function (118, 121, 123, 133). 
However, in 2 large randomized controlled trials, MARS failed to demonstrate a significant 
impact on patient survival (124, 125). 
Until today, 20 patients from 5 reports are found in the literature in whom MARS was used as 
a treatment for PHLF (119, 127-129, 168). Survival was very poor in all reports, and a lack of 
standardized treatment protocol was apparent. In contrast, we observed a 44% 90-day 
survival in patients with primary PHLF defined according to the Balzan criteria (100). An 
obvious difference between survivors and non-survivors was the number of performed 
MARS cycles. All survivors received a minimum of 4 treatments. This is in line with earlier 
reports of MARS treatment in other types of liver failure where a minimum of 3 consecutive 
treatments was considered necessary in order to achieve adequate treatment effect (125, 169, 
170). In patients with secondary PHLF, which was defined as PHLF as a consequence of 
postoperative complication, MARS treatment was applied in the later postoperative course, 
with zero 90-day survival. Poor results in this situation were observed earlier (128, 129) and 
in conclusion, MARS treatment does not seem to be justified in this situation. The timing of 
MARS treatment is most likely a very critical issue. Liver regeneration is initiated 
immediately at the end of hepatectomy (41). Recent studies suggested bilirubin on POD 3 
(171) or phosphorus levels on POD 2 (172) as early, independent prognostic factors for 
predicting PHLF. So, theoretically, it might be beneficial to start with MARS even earlier 
than POD 5, but only if evidence for the power of predictive scores earlier than POD 5 has 
been strengthened. When the PHLF situation is established, it can be speculated about several 
beneficial effects of MARS on liver regeneration in order to turn around the clinical picture 
and allow the liver to regain normal function. Given its potential to provide anti-
inflammatory effects and to bind reactive oxygen species (ROS) (173), detoxification of 
Albumin might increase its anti-oxidative capacity and thus decrease oxidative stress in the 
regenerating liver. In addition, several effects on cytokines important for liver regeneration 
have been observed in patients with acute liver failure (ALF) or acute-on-chronic liver failure 
(AoCLF), e.g., an increase of hepatocyte growth factor (HGF) and decrease of IL-6 and TNF-
α (135). Those have been identified as key players of liver regeneration (41), thus modulation 
of plasmatic concentrations might positively influence the regenerative capacity of the liver 
(134). Even portal hypertension has been recognized as a major risk factor for PHLF (110). In 
accordance, the potential of MARS of lowering portal pressure (120, 133) might contribute to 
improved patient outcome, too.   
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In summary, we made several observations in this study which, together with findings from 
other reports, served as background for the development of a treatment protocol to validate 
safety and feasibility of early MARS treatment in a prospective pilot study. In our opinion, it 
is essential to start treatment as early as possible, based on the available literature on POD 5 
when the Balzan criteria are fulfilled. In order to avoid “under treatment”, a minimum of 5 
treatment cycles should be applied. Patients with secondary PHLF should not be treated with 
MARS. 
6.3.4 Study IV 
In our pilot study, we found early MARS treatment to be safe and feasible in patients with 
PHLF. In-hospital mortality was considerably lower compared to a historical control group. 
Half of the patients were alive 1-one year post-hepatectomy without signs of disease 
recurrence.  
In recent years, several studies were aiming to demonstrate survival benefits for patients with 
acute liver failure. However, MARS could not show a survival benefit in large randomized 
controlled trials for patients with neither ALF (125) nor AoCLF (124). Regarding the PHLF 
situation, there were some publications in the early 2000´s, only reporting results not 
supporting the use of MARS. However, these studies were not performed in homogeneous 
patient populations, included just a very small number of patients, and there was no 
standardized treatment protocol (16, 127-129, 168). Thus, our pilot study is to our knowledge 
the first one with a strict study protocol and a comparable study population.   
With regards to safety and feasibility, we observed no major complications. In two patients, 
there were problems with the central venous line making it necessary to replace lines one and 
two times, respectively. The MARS filter clotted in one treatment session. As we did not 
observe any bleeding complication, this illustrates a very good balance between 
anticoagulation in order to avoid clotting of the MARS filter and hemostasis in the patient to 
avoid bleeding after major surgery. Using local citrate anticoagulation (139), we did not 
observe severe disturbance of electrolyte balance either. However, in one patient we observed 
an unexpected clinical course. Even in this patient, MARS was started according to the 
protocol. After the first MARS session, we observed a moderate decrease in bilirubin. MARS 
was continued according to the protocol and there was a slight decrease in bilirubin even after 
the following treatments. However, the increase in bilirubin in-between the MARS cycles 
was so massive, that the overall increase of bilirubin ended up with a peak around 1000 
micromol/L. Along with the hyperbilirubinemia, there was just a moderate increase of INR 
and no signs of encephalopathy. Such a response related to MARS has not been described 
before in the literature ,and the exact mechanism behind remains, despite extensive 
consultations with specialists in the field, unclear. Regarding feasibility, we experienced 
minor problems, mainly related to the fact that MARS treatment requires patient transfer to 
the ICU. As resources are limited, PHLF patients without further indication of ICU treatment 
than MARS, were conflicting with those patients being in real need of ICU treatment. Thus, 2 
treatment cycles had to be interrupted. This did not lead to a protocol violation, but a more 
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flexible use of MARS could help to avoid this issue in the future and would be highly 
appreciated. Our study protocol was designed based on our own experience (Paper III) and 
observations made in patients with different causes of liver failure. For the PHLF situation, it 
is probably crucial to initiate treatment early and consequently. According to earlier reports, 3 
consecutive MARS treatments were considered to be the minimum amount in order to 
achieve a sufficient treatment result (169, 170). In this pilot study, we definitely want to avoid 
“under-treatment”. This was the reason for a scheduled minimum of 5 treatment cycles and a 
minimum of 3, if the MARS treatment was interrupted. The time point of treatment onset is 
another critical question, and in our opinion, it has to be based on a valid risk assessment. 
However, as liver regeneration starts immediately after liver resection (41), supportive 
measures probably should be initiated as early as possible. Currently, there is no solid 
possibility to predict PHLF during the first days after hepatectomy. In clinical practice and 
according to our historical control group, the 50:50 criteria (100) serves as the best predictive 
tool in order to predict PHLF related mortality. Thus, until new evidence is available, we 
suggest these criteria when choosing patients for MARS treatment due to PHLF.  
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7 CONCLUSIONS 
 
The papers included in this thesis allow the following to be concluded: 
Hepatectomies are performed with low mortality and good long-term results even in a 
population-based setting. 
Risk factors for increased mortality include the extent of liver resection and diagnosis 
primary liver or bile duct cancer. 
Re-do resection improves long-term survival in a selected group of patients.  
Centralization of cancer surgery implies improved patient outcome. 
Post-hepatectomy liver failure is considered to be the cause of death in about 40% of all 
patients positive for 90-day mortality. 
Thus, PHLF is the single most important reason for 90-day mortality following hepatectomy 
even in a population-based setting. 
A great effort is needed to further improve avoidance and treatment of PHLF.  
Based on retrospective experience, MARS treatment cannot be recommended as treatment 
for patients with PHLF in the later course after hepatectomy and in patients with secondary 
PHLF.  
In a prospective cohort study, it was safe and feasible to use MARS in patients with primary 
PHLF. 
Applying a strict treatment protocol, early and frequent MARS treatment improved both short 
and long-term survival of patients with PHLF compared to a historical control group. 
A prospective, randomized trial is highly warranted to evaluate the impact of early MARS 
treatment on survival in patients with PHLF. 
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8 FUTURE RESEARCH 
 
Since the national Swedish liver register was introduced in 2009, this register offers new and 
compelling opportunities for population-based register studies in the future. In recent years 
there was a shifting trend for hepatectomies, leaving major and extended hepatectomy when 
possible and performing parenchyma sparing surgery instead. This paradigm shift, along with 
better and strictly defined standards regarding pre-operative workup before hepatectomy, the 
incidence and thus the mortality associated with PHLF should decrease. After validation of 
the national liver register, we plan a follow-up study in order to evaluate incidence and 
mortality related to PHLF in more recent years. Based on register data, better insights in risk 
factors and validation of different prognostic models should be possible even in a population-
based setting. 
Based on the results of paper IV, we have designed a prospective, randomized, controlled 
multicenter trial in order to evaluate the impact of MARS on short-term mortality and long-
term outcome in patients with PHLF. The study was designed together with collaborators 
from Hospital Clinic, Barcelona. Ethical board approval was already obtained and currently, 
the application to the approving authorities is prepared. Several centers in Europe have 
expressed both their interest and willingness to participate.  
Successful treatment of PHLF with MARS has raised several scientific questions regarding 
existing knowledge and understanding of liver regeneration after partial hepatectomy and the 
pathophysiology of PHLF. Within the RCT, blood samples are going to be collected in order 
to analyze changes related to MARS treatment of several relevant factors important for liver 
resection. Volumetric measurements of the future liver remnant will be performed to allow 
for correlation between liver volume and function. 
As avoidance still represents the best treatment of PHLF, results from the RCT hopefully will 
contribute to an even better pre-operative patient selection and understanding of PHLF in 
order to minimize the incidence of PHLF. In our department, several translational projects are 
ongoing regarding pre-operative workup of patients scheduled for liver resection, like 
evaluation of different techniques to increase future liver remnant, and these collaborations 
hopefully will continue even in future research projects. 
 46 
  47 
9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Leverkirurgi anses idag vara standardbehandlingen för de flesta tumörer i lever och gallvägar.  
Sedan 1990-talet har leverkirurgin genomgått en betydande utveckling. Det finns trots denna 
utveckling fortfarande en del diagnoser och ingrepp som har sämre prognos och högre risk 
vid leverkirurgi. En av de mest fruktade komplikationerna efter en leverresektion är 
postoperativ leversvikt. I vanliga fall fungerar det bra att ta bort upp till 80% av den totala 
levervolymen. Vissa diagnoser, som exempelvis gallgångscancer, är ofta förknippade med 
gallstas vilket leder till sämre leverfunktion inför operation. Dessutom kan förbehandling 
med cellgifter leda till nedsatt leverfunktion. Även andra sjukdomar som hjärtsvikt eller 
diabetes kan påverka leverfunktionen negativt. I dessa fall är leverns kapacitet att återhämta 
sig nedsatt och risken för post-hepatektomi leversvikt (PHLF) större. Trots att man känner till 
flera faktorer som inverkar negativt på leverns förmåga att återbildas drabbas ändå en del 
patienter av PHLF. När PHLF uppstått finns ingen effektiv behandling mot detta tillstånd. En 
möjlig behandling mot PHLF är så kallad leverdialys, som renar patientens blod från olika 
slagg produkter. Tekniken liknar vanlig njurdialys, men är mer effektiv avseende rening av 
leverspecifika ämnen. Erfarenheterna av leverdialys är nedslående trots att det teoretiskt finns 
flera effekter av en sådan behandling som skulle kunna bidra till leverns återhämtning. En 
konsekvent och intensifierad användning av leverdialys hos patienter med PHLF har inte 
tidigare studerats. 
Det här avhandlingsarbetet har som målsättning att studera olika aspekter av leverkirurgi och 
PHLF. I första och andra arbetet har vi genomförd populationsbaserade studier och undersökt 
hur överlevnaden ser ut för patienter med olika sjukdomar efter leverkirurgi och vilken 
betydelse PHLF har för dödlighet inom 90 dagar efter leverkirurgiska ingrepp. Olika register 
har använts för att samla in data som sedan har analyserats för att kunna besvara de 
vetenskapliga frågeställningar. Leverkirurgi i Sverige har låg dödlighet och god 
långtidsöverlevnad, vilket ligger i nivå med tidigare studier. Dödlighet och överlevnad 
varierar dock kraftigt, beroende på storlek av ingreppet och på bakomliggande diagnos. 
Centralisering av stor kirurgi till Universitetssjukhus verkar ha positiv effekt på både 
komplikationer till ingreppet och långtidsöverlevnad. Det finns knappt några 
populationsbaserade studier i litteraturen. Möjligen kan man ur våra resultat dra slutsatsen av 
att vi i Sverige varit för restriktiva när det gäller att välja ut patienter för leverkirugiska 
ingrepp. I det andra arbete har vi kunnat påvisa att PHLF bidrar till eller är själva orsaken till 
död hos drygt 40% av alla patienter som dör inom 90 dagar efter leverkirurgi. Några 
riskfaktorer som är kända från tidigare studier har kunnat bekräftas i vår populationsbaserade 
studie. Det tredje arbetet hade som målsättning att undersöka om leverdialys har en positiv 
effekt på patienter med PHLF. Retrospektiv analys genomfördes på två universitetssjukhus, 
Karolinska Universitetssjukhuset Huddinge och Hospital Clinic Barcelona. Totalt 
identifierades 13 patienter och överlevnaden för dessa patienter var dålig. Vid granskning av 
detaljer vid behandlingen av dessa patienter har vi dock kunnat identifiera skillnader i 
överlevnad beroende på behandlingstid och intensitet. Detta gav oss hypotesen för att designa 
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en prospektiv studie för att undersöka säkerheten och effekten av tidig leverdialys hos 
patienter med PHLF efter leverkirurgi. Behandlingsprotokollet syftade på en tidig och mer 
intensiv behandling så snart som möjligt efter leverkirurgi om patienten visade på tydliga 
tecken för PHLF. Totalt har 10 patienter ingått i studien och behandlats på Karolinska 
Universitetssjukhuset Huddinge och vi kunde konstatera att det var säkert och effektivt att 
behandla patienter enligt studiens behandlingsprotokoll. Både 90 dagars dödlighet och 
långtidsöverlevnad var betydligt bättre jämfört med historiska kontroller från vårt eget 
sjukhus och med tidigare rapporterade resultat på svår PHLF. Dessa resultat måste dock 
bekräftas i en större studie där man lottar patienter med PHLF till standardbehandling enbart 
eller till standardbehandling plus leverdialys.  
Sammanfattningsvis har de genomförda arbetena lett till resultat som kommer att ha 
betydelse för planering av leverkirurgi i Sverige i framtiden och som ger ett visst hopp om en 
effektiv behandling för patienter med leversvikt efter leverkirurgiska ingrepp. 
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